Synthetics Biologics Inc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 72.95. In total, the insiders bought 22 165 350 and sold 5 656 317 SYN shares in the last 100 trades.

Insider Power

(Last 100 transactions)
72.95
Buy 22 165 350 Shares
Sell 5 656 317 Shares

Historical Insider Trades

Date Type Action Person Amount
Dec 14, 2023 Stock Options (right to buy) Buy Shallcross Steven A 700 000
Dec 14, 2023 Stock Options (right to buy) Buy Wolf Jeffrey Alan 110 000
Dec 14, 2023 Stock Options (right to buy) Buy Kraws Jeffrey J 110 000
Dec 14, 2023 Stock Options (right to buy) Buy Monahan John J 110 000
Jun 07, 2023 Common Stock Buy Shallcross Steven A 14 000
Jun 06, 2023 Common Stock Buy Shallcross Steven A 26 000
Feb 10, 2023 Common Stock Buy Shallcross Steven A 25 000
Feb 02, 2023 Common Stock Buy Shallcross Steven A 25 000
Jan 25, 2023 Common Stock Buy Shallcross Steven A 25 000
Jan 20, 2023 Common Stock Buy Shallcross Steven A 25 000
Dec 29, 2022 Common Stock Buy Shallcross Steven A 100 000
Dec 15, 2022 Stock Options (right to buy) Buy Kraws Jeffrey J 100 000
Dec 15, 2022 Stock Options (right to buy) Buy Wolf Jeffrey Alan 100 000
Dec 15, 2022 Stock Options (right to buy) Buy Monahan John J 100 000
Dec 15, 2022 Stock Options (right to buy) Buy Shallcross Steven A 475 000
Dec 15, 2022 Stock Options (right to buy) Buy Tufaro Francis 100 000
Mar 22, 2022 Common Stock Buy Tufaro Francis 0
Dec 23, 2021 Stock Options (right to buy) Buy Wolf Jeffrey Alan 200 000
Dec 23, 2021 Stock Options (right to buy) Buy Shallcross Steven A 650 000
Dec 23, 2021 Stock Options (right to buy) Buy Monahan John J 200 000
Dec 23, 2021 Stock Options (right to buy) Buy Kraws Jeffrey J 200 000
May 10, 2021 Common Stock Buy Shallcross Steven A 50 000
Dec 30, 2020 Stock Options Buy Wolf Jeffrey Alan 150 000
Dec 30, 2020 Stock Options Buy Shallcross Steven A 450 000
Dec 30, 2020 Stock Options Buy Monahan John J 150 000
Click to get the best stock tips daily for free!

About Synthetics Biologics Inc

Synthetics Biologics Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), ... SYN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT